Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.36 |
| ▸ | MICA | Q29983 | 1/20 | 0.36 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036728 | 0.83 | ROCK2 (0.44) | ROCK2FFAR1ROCK1POLBKMT2A | |
| SCHEMBL27406042 | 0.82 | CACNA1B (0.43) | ROCK2PRKG1TACR3RAB9A | |
| SCHEMBL29861275 | 0.82 | CACNA1B (0.43) | ROCK2PRKG1TACR3RAB9A | |
| SCHEMBL25624750 | 0.81 | CACNA1B (0.38) | ROCK2PRKG1RAB9A | |
| SCHEMBL24036748 | 0.81 | CACNA1B (0.38) | ROCK2PRKG1RAB9A | |
| SCHEMBL24036727 | 0.81 | KCNA5 (0.47) | TACR3WDR5POLBKMT2A | |
| SCHEMBL24036731 | 0.81 | WDR5 (0.50) | TACR3WDR5CNR2KMT2A | |
| SCHEMBL24036950 | 0.81 | TACR3 (0.39) | ROCK2PRKG1TACR3ROCK1RAB9A | |
| SCHEMBL24037112 | 0.80 | ROCK2 (0.38) | ROCK2PRKG1FFAR1KMT2A | |
| Hydrochloric Acid SCHEMBL29861388 | 0.79 | ROCK2 (0.38) | ROCK2PRKG1FFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2021230325-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | 宇部興産株式会社 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | ROCK2 3623/4885PRKG1 4133/4885TACR3 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.